HF
IBO

HRT Financial’s Impact BioMedical IBO Stock Holding History

HRT Financial’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,533
Closed -$6K – 4954
2025
Q4 		$6K Buy
+13,533
New +$7.16K ﹤0.01% 3064
2025
Q3 		– Sell
-10,326
Closed -$6K – 3857
2025
Q2 		$6K Sell
10,326
-57,832
-85% -$32.4K ﹤0.01% 2481
2025
Q1 		$59K Buy
+68,158
New +$118K ﹤0.01% 2225
2024
Q4 		– Sell
-12,502
Closed -$25K – 3425
2024
Q3 		$25K Buy
+12,502
New +$29.6K ﹤0.01% 2174

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

HRT Financial's IBO Position: Q1 2026 in Review

HRT Financial sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 13,533 shares — an estimated $6K sold.

HRT Financial first reported a position in IBO in Q3 2024 and held it in 4 quarters. The position peaked at $59K in Q1 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • HRT Financial reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 13,533 Impact BioMedical shares in Q1 2026, an estimated $6K.
  • HRT Financial first reported a position in Impact BioMedical in Q3 2024 and held it in 4 quarters.
  • HRT Financial's Impact BioMedical position peaked at $59K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.